Start Investing

Novum Alpha - Daily Analysis 23 December 2020 (10-Minute Read)

Happy holidays and from all of us here at Novum Alpha, a very Merry Christmas!


As we head into the holiday season, I would like to personally thank you for opening up these emails and sharing the content. 
 
Looking back over the past year, I am humbled by the overwhelming response to our Daily Analysis and Weekend Edition and on behalf of the entire team here at Novum Alpha, thank you for your continued support. 
 
Novum Alpha's Daily Analysis will be taking a short break till the end of the year to re-tool and create new and even more engaging content for 2021. 
 
As you have journeyed with us over the past year, riding the markets and divining opportunities, we here at Novum Alpha would like to wish you the very best in the year ahead, with vaccines, travel and an abundance of possibilities to fill your investment world. 
 
Thank you, Merry Christmas and Happy New Year!
 

In brief (TL:DR)

 
  • U.S. stocks were muted heading into the last week of 2020 with typically low holiday volumes with the S&P 500 (-0.21%) and the blue-chip Dow Jones Industrial Average (-0.67%) down marginally while the tech-centric Nasdaq Composite (+0.51%) was higher as pandemic-investment themes took hold of the narrative. 
  • Asian stocks opened mostly higher on Wednesday as U.S. stock futures look to shrug off the mutating coronavirus pandemic and on news that existing vaccines may be up to the task of addressing the mutation. 
  • U.S. 10-year Treasury yields dipped to 0.912% and look set to fall further as investor appetite for risk so close to the year end falls (yields fall when bond prices rise). 
  • The dollar was steady, as investors avoided making any major decisions, particularly with regards to risk, so close to the year's end. 
  • Oil fell sharply with January 2021 contracts for WTI Crude Oil (Nymex) (-1.45%) at US$46.34 from US$47.02 as traders continued to bet that borders would not reopen quite as quickly, especially given the swift response to close off the United Kingdom to the rest of Europe. 
  • Gold was mostly unchanged with February 2021 contracts for Gold (Comex) (+0.04%) rising to US$1,871.00 from US$1,870.30. 
  • Bitcoin (+5.07%) reversed sharply to US$23,830 as inflows into exchanges surged ahead of outflows and with the impending lawsuit against XRP turning investor sentiment sour on non-Bitcoin cryptocurrencies (inflows typically suggest that investors are selling Bitcoin in anticipation of further price decreases). 
 

In today's issue...

 
  1. A New Coronavirus Mutation Won't Kill the Buzz in Markets  
  2. In China It's Best to Keep Your Head Down & Make Money 
  3. SEC's Lawsuit will Ripple Through the Entire Cryptocurrency Industry 
And as we round off the year, don't miss the last webinar of Novum Alpha in 2020: Women in Crypto #1: Feminine Energy "To Da  Moon"
 
Find out how women are powering the cryptocurrency and blockchain space to even greater heights and the challenges that they face in this industry.
 
📆 Date & Time: Tonight, Wednesday 23 Dec - 8PM (GMT+7)
 

Market Overview

 
Mutation? No big deal. 
 
At least according to coronavirus vaccine developers who are confident that their vaccines are up to scratch to face down the mutating coronavirus first discovered in the United Kingdom. 
 
Not much at this stage will slow markets down, with government and central bank intervention almost guaranteed to buoy markets. 
 
In Asia, markets were higher with Tokyo's Nikkei 225 (+0.14%), Sydney’s ASX 200 (+0.63%), Hong Kong's Hang Seng Index (+0.16%) and Seoul’s KOSPI (+0.24%) all up slightly in the morning trading session despite signs that the pandemic may be worsening. 
 
Things may be bad with fresh lockdowns and renewed travel restrictions, but in the stock markets, everyday feels like Christmas. 
 
1. A New Coronavirus Mutation Won't Kill the Buzz in Markets
 
  • Markets are likely to shrug off the impact of a coronavirus mutation coming out of the United Kingdom 
  • Central bank and government intervention will continue to ensure that investors have sufficient liquidity and appetite for risk 
 
While a mutated coronavirus is scary, it’s not scary enough to keep investors away from the markets and hunkering down in their bunkers.
 
And while global stocks and key commodities like oil slumped and bond prices surged on Monday after investors reacted to the new strain of the coronavirus that emerged in the United Kingdom, by the afternoon, it was as if all was forgotten, with the S&P 500 making up most of the lost ground.
 
To be sure, short term disruptions and often disastrous public health situations in parts of the world are largely ignored by financial markets on the core belief that extraordinary circumstances will be met with extraordinary government and central bank support.
 
That faith in governments’ willingness and ability to intervene in times of crisis bolsters investor faith in the avoidance of mass unemployment, loss of income and to ward off a cascade of bankruptcies.
 
Government and central bank intervention has emboldened investors to look further ahead and served as a driver of extreme valuations, unlike the irrational exuberance more typical of stock market bubbles.
 
And while the S&P 500 is trading at almost 27 times price-to-earnings, that’s based on the past year’s earnings, whereas forecast earnings put it at just 19 times over the next two years.
 
In other words, take 2020 as a mulligan, a do-over if you will, where governments and central banks hit the “pause” button while the world sorts things out.
 
And while stocks of IAG (+5.80%), owner of British Airways fell by over 7% on Monday, the difference between a 72% collapse in share price and a 78% share price given the circumstances is more perceived than actual, and the stock has since rebounded. 
 
The bigger question is whether the coronavirus mutation is likely to lead to longer term public health implications.  
 
For now, leading scientists say that it won’t.
 
And both Pfizer (-1.71%) and Moderna (-8.98%) are testing their existing coronavirus vaccines on the new mutated strain of the coronavirus, with Moderna expecting that it will work against variants.
 
And if science continues to support the consensus belief that the mRNA-based coronavirus vaccines will be effective, the economic outlook is unlikely to change. 
 
 
2. In China It's Best to Keep Your Head Down & Make Money
 
  • The scuttled IPO of Ant Group, a quasi-digital bank, insurance and investment firm has hit the skids as Beijing makes clear to tech entrepreneurs that it will not tolerate public criticism 
  • Investors into Chinese tech firms may want to check if the CEOs they are backing are content to toe the line as it will directly affect their investment prospects 
 
Jack Ma has always had a flamboyant personality.
 
Despite not ever having written a single line of code, he built an e-commerce giant in the form of Alibaba (+0.32%) and is one of the world’s richest men.
 
If Berkshire Hathaway’s (-0.78%) annual meetings are Warren Buffett’s fireside chat then, Alibaba’s annual meetings are more like Jack Ma’s personal rock concerts, complete with fake hair and tattoos.  
 
But in October, on the eve of an impending US$34 billion IPO of financial services giant Ant Group, Ma’s comments at a Shanghai conference would prove to be one last rock concert too many.
 
Taking to the stage at the conference, Ma proceeded to roast the anachronistic government regulation that he blamed for stifling innovation in China, lambasting the Chinese financial system and by extension the powers that be.
 
A vignette to widely held, but rarely expressed frustration amongst China’s entrepreneurial class, Ma went off on a 20-minute roast that was a vintage performance by the famously outspoken executive, known for his confident swagger and searing rhetoric.
 
But this proved to be one performance too many for the ruling class in Beijing and by November, the Chinese Communist apparatchiks scuttled the Ant Group public offering, lowered tough new antitrust rules and shaved off about US$140 billion from the market cap of Ma’s Alibaba.
 
Billionaires are known to have expensive taste, but at approximately US$43 million a word (translated to English), Ma’s was a very expensive speech to say the least.
 
Ma has since disappeared from public view, and his empire is under the microscope of regulators, but he is believed to still be in China.
 
While most believe that Ma is not headed for a personal or financial downfall, his rebuke is part of Beijing’s greater effort to reign in the power and influence of its tech behemoths.
 
Ma’s castigation also serves as a warning to the heads of other tech giants, including Baidu (-0.94%) CEO Robin Li and founders of Tencent (+0.26%), Ma Huateng, Chen Yidan and Zhang Zhidong as well as other Chinese tech firms. 
 
In the Chinese context, there’s no such thing as “too big to fail,” and although once hailed as drivers of economic prosperity and symbols of the country’s technological prowess, the empires built by these tech tycoons are now increasingly being viewed as a threat to the Communist Party.
 
But there was method to Ma’s apparent madness.
 
Aware of the impending avalanche of regulations that would attempt to bring the realm of digital finance within the ambit of the legacy financial system, Ma was making a last-ditch attempt to deflect the inevitable regulatory onslaught.
 
Admirable, but ultimately futile as instead of staving off regulations, it accelerated them – within a week, China’s antitrust regulator issued proposed new anti-monopoly rules, a veiled threat to Ma and his fellow Chinese tech titans to tone down the swagger.
 
Ma’s spectacular fall from grace has been years in the making.
 
Part of a cadre of self-made billionaires, Ma and his fellow tech moguls created their fortunes despite the Chinese Communist Party, instead of relying on powerful Party connections to ply their trade.
 
Ma and other tech founders have constantly run the gauntlet that is tech entrepreneurship in China, navigating the conflicting demands of Beijing, with the independence of receiving foreign investment.
 
And while the west encourages, even idolizes, flamboyant CEOs in the mold of Richard Branson and Elon Musk, the Chinese Communist Party bristles at any attempt to divert focus away from loyalty to the Party.
 
As the dust settles, the failed IPO of Ant Group serves as a reminder to all Chinese tech CEOs – you can make money, you can have a powerful company, but you’ve got to tow the party line. 
 
3. SEC's Lawsuit will Ripple Through the Entire Cryptocurrency Industry
 
  • U.S. Securities and Exchange Commission comes after Ripple and XRP, the world's third largest cryptocurrency by market cap 
  • Immediate effect of lawsuit has been to bolster demand for Bitcoin, with other cryptocurrencies proving to be too risky for institutional investors just dipping their toe into the cryptocurrency pool 
 
Even as members of the Trump administration are packing up, sending out resumes or scrubbing evidence that they had any involvement in the last four years of Trump’s presidency, there’s still plenty of time to throw a grenade in the room.
 
Despite being no fan of cryptocurrencies and leaving the Securities and Exchange Commission (SEC) at the end of the year, outgoing SEC Chairman Jay Clayton has seen it fit to sue Ripple Labs, alleging that its XRP, the cryptocurrency that Ripple issued, has violated securities law.
 
Over the past few years, the SEC has had a winning record against startups which it alleges to have breached securities laws by raising money through the sale of cryptocurrencies, but these companies were minor compared to Ripple.
 
With a US$10 billion valuation in its most recent funding round in 2019, XRP is also the world’s third-largest cryptocurrency by market value, but fell by almost a fifth on the news.
 
And therein lies the irony, even though XRP may be decentralized, Ripple itself is a prime target for regulators.
 
Early on, Ripple devolved control over XRP to developers who receive XRP as a reward for maintaining and advancing the XRP blockchain.
 
But key to the SEC’s claims is that Ripple, as well as CEO Brad Garlinghouse and co-founder Chris Larsen, who were named in the suit, had sold XRP tokens in 2013 worth some US$1.38 billion in an unregistered securities offering.
 
The main crux of the lawsuit is whether the sale of XRP was a security that should have been registered with the SEC, providing the SEC and the public with disclosures about Ripple’s business model, risks and financial condition.
 
According to the SEC lawsuit, Ripple had marketed and sold XRP wholly as a speculative asset, not a currency.
 
The fallout from the SEC lawsuit will ripple across the cryptocurrency industry, especially because XRP is like Bitcoin and Ether in certain ways, but different in significant ways that sparked the SEC lawsuit.
 
If successful, the SEC may set even clearer ambits of what would and wouldn’t fall foul of securities laws, but the action itself appears arbitrary and may have a chilling effect on prospective cryptocurrency issuances.
 
The timing of the SEC lawsuit however is curious, especially given that XRP has been around for a while, and with SEC Chairman Jay Clayton heading for the exit from the SEC in just over a week.
 
And while the SEC has publicly suggested that neither Bitcoin nor Ether are securities, the agency has been cautious not to suggest any other cryptocurrencies aren’t.
 
Which means that technically any cryptocurrency could fall afoul of securities laws if the SEC deems in its sole purview that they are a target.
 
And that could mean institutional investors who have just waded into the cryptocurrency space may stick to the “tried and tested” with greater focus on Ether and Bitcoin, to the detriment of other cryptocurrencies. 
 

What can Digital Assets do for you?

 
While markets are expected to continue to be volatile, Novum Alpha's quantitative digital asset trading strategies have done well and proved resilient.
 
Using our proprietary deep learning and machine learning tools that actively filter out signal noise, our market agnostic approach provides one of the most sensible ways to participate in the nascent digital asset sector. 
 
If this is something of interest to you, or if you'd like to know how digital assets can fundamentally improve your portfolio, please feel free to reach out to me by clicking here.  
Looking to trade cryptocurrency yourself? Then why not try CryptoHero, a member of the Novum Group. 
 
Enjoy some of the high performing algorithms that Novum Alpha uses, absolutely free! 
 
Because you can't be up 24 hours trading cryptocurrency markets, CryptoHero's free bots do the trading for you. 
 
Simple and intuitive for crypto beginners to set up and run, CryptoHero is currently available on the Web and iOS with an Android version ready in 2021.
 
Try our one click copy bot settings with the button below and enjoy 1-month Premium Subscription absolutely free! 
DOWNLOAD APP & TRY IT FREE

Dec 23, 2020

Get the Novum Alpha newsletter delivered to your inbox daily


Important Risk Information



The information provided on this site is for informational purposes only. It is not to be construed as investment advice or a recommendation or offer to buy or sell any security. Prospective clients should always obtain and read an up-to-date product and/or services description or prospectus before deciding whether to invest. Any views expressed herein are those of Novum Alpha SPC (“the Company”) are based on available information, and are subject to change without notice. There are no guarantees regarding the achievement of investment objectives, target returns, or measurements such as alpha, tracking error, asset weightings and other information ratios. The views and strategies described may not be suitable for all clients. The Company does not provide tax or legal advice. Prospective subscribers should consult with a tax or legal advisor before making any investment decision. Investing in any investment product entails risks and there can be no assurance that the Company avoid incurring losses or achieve any of a prospective subscriber’s investment goals.


Performance quoted represents past performance, which is no guarantee of future results. Investment and principal value will fluctuate, so you may have a gain or loss when assets are sold. Current performance may be higher or lower than that quoted product’s expenses and other liabilities, and such product may be unable to meet its investment objective